PCOS (polycystic ovary syndrome)
Hormonal and metabolic disorder affecting ~10% of women of reproductive age — irregular cycles, hyperandrogenism, insulin resistance, infertility, endometrial cancer risk.
What changes during this transition
PCOS is fundamentally a metabolic + endocrine disorder — ~70% of patients have insulin resistance, which drives the hyperandrogenism and ovulatory dysfunction. Improving insulin sensitivity reduces androgens, restores ovulation, and lowers endometrial cancer risk; this is the primary therapeutic lever. GLP-1 agonists (semaglutide, tirzepatide) are ADA-acknowledged first-line tools when metabolic-PCOS dominates — emerging evidence base is the strongest in the library for this indication. Tesamorelin is the partial GH-axis exception per clamp data (doesn't worsen glycemia — most GH-axis peptides do, and are CONTRAINDICATED in IR-PCOS). Kisspeptin has a narrow case as an oocyte-maturation trigger in IVF with lower OHSS risk versus hCG — REI-managed within research-protocol-adjacent settings. Standard PCOS care still leads: letrozole for ovulation induction, hormonal contraception for cycle regulation when fertility isn't the goal, metformin for IR.
Important caveat
PCOS deserves OB-GYN or endocrinology coordination — peptide selection should follow phenotype assessment (lean PCOS vs IR-PCOS) via fasting insulin, HOMA-IR, and a metabolic panel. CRITICAL: GH-axis peptides (CJC-1295, ipamorelin, MK-677, sermorelin) are CONTRAINDICATED in insulin-resistant PCOS — chronic GH stimulation works AGAINST the primary therapeutic goal. Endometrial cancer risk is 3× baseline in PCOS — any growth-promoting peptide layered on top warrants explicit OB-GYN surveillance coordination. If fertility is the goal, REI involvement is the precondition, not a peptide stack.
Peptides editorially relevant to pcos (polycystic ovary syndrome)
4 peptides from the library — each evidence-tiered honestly.
- SemaglutideTier 1
GLP-1 receptor agonist
The most-studied GLP-1 agonist in modern medicine, with Tier 1 evidence for diabetes, weight loss, and major adverse cardiovascular events.
- TirzepatideTier 1
GLP-1 / GIP dual agonist
FDA-approved dual incretin agonist with the strongest weight-loss and glycemic data in this library.
- KisspeptinTier 2
KISS1R agonist (hypothalamic neuropeptide)
Sits at the very top of the reproductive axis — triggers the cascade that produces sex hormones. Strong clinical-research evidence for hypogonadism and IVF use; off-label 'natural T' community use in healthy men runs ahead of the data.
- TesamorelinTier 1
GHRH analog
FDA-approved for HIV-associated lipodystrophy. Off-label use for general fat loss is meaningfully less supported.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.